Literature DB >> 30004605

Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations.

Suji Lee1, Ji Young Huh2, David M Turner3,4, Soohyeon Lee1, James Robinson5,6, Jeremy E Stein5, Sung Han Shim1, Chang Pyo Hong7, Myung Seo Kang2, Masato Nakagawa8, Shin Kaneko8, Mahito Nakanishi9, Mahendra S Rao10, Andreas Kurtz11, Glyn N Stacey12, Steven G E Marsh5,6, Marc L Turner4,13, Jihwan Song1,13.   

Abstract

Although autologous induced pluripotent stem cells (iPSCs) can potentially be useful for treating patients without immune rejection, in reality it will be extremely expensive and labor-intensive to make iPSCs to realize personalized medicine. An alternative approach is to make use of human leukocyte antigen (HLA) haplotype homozygous donors to provide HLA matched iPSC products to significant numbers of patients. To establish a haplobank of iPSCs, we repurposed the cord blood bank by screening ∼4,200 high resolution HLA typed cord blood samples, and selected those homozygous for the 10 most frequent HLA-A,-B,-DRB1 haplotypes in the Korean population. Following the generation of 10 iPSC lines, we conducted a comprehensive characterization, including morphology, expression of pluripotent markers and cell surface antigens, three-germ layer formation, vector clearance, mycoplasma/microbiological/viral contamination, endotoxin, and short tandem repeat (STR) assays. Various genomic analyses using microarray and comparative genomic hybridization (aCGH)-based single nucleotide polymorphism (SNP) and copy number variation (CNV) were also conducted. These 10 HLA-homozygous iPSC lines match 41.07% of the Korean population. Comparative analysis of HLA population data shows that they are also of use in other Asian populations, such as Japan, with some limited utility in ethnically diverse populations, such as the UK. Taken together, the generation of the 10 most frequent Korean HLA-homozygous iPSC lines serves as a useful pointer for the development of optimal methods for iPSC generation and quality control and indicates the benefits and limitations of collaborative HLA driven selection of donors for future stocking of worldwide iPSC haplobanks. Stem Cells 2018;36:1552-1566.
© 2018 The Authors Stem Cells published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Entities:  

Keywords:  Cord blood banks ; Genomic stability ; Haplobanking ; Human leukocyte antigen ; Immune rejection; Induced pluripotent stem cells

Mesh:

Substances:

Year:  2018        PMID: 30004605     DOI: 10.1002/stem.2865

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  19 in total

Review 1.  Induced Pluripotent Stem Cell-Derived Endothelial Cells: Overview, Current Advances, Applications, and Future Directions.

Authors:  Sae Jang; Alexandra Collin de l'Hortet; Alejandro Soto-Gutierrez
Journal:  Am J Pathol       Date:  2019-01-14       Impact factor: 4.307

Review 2.  Pluripotent stem cell-based gene therapy approach: human de novo synthesized chromosomes.

Authors:  Sergey A Sinenko; Sergey V Ponomartsev; Alexey N Tomilin
Journal:  Cell Mol Life Sci       Date:  2020-10-03       Impact factor: 9.261

3.  Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells.

Authors:  Bo Wang; Shoichi Iriguchi; Masazumi Waseda; Norihiro Ueda; Tatsuki Ueda; Huaigeng Xu; Atsutaka Minagawa; Akihiro Ishikawa; Hisashi Yano; Tomoko Ishi; Ryoji Ito; Motohito Goto; Riichi Takahashi; Yasushi Uemura; Akitsu Hotta; Shin Kaneko
Journal:  Nat Biomed Eng       Date:  2021-05-17       Impact factor: 25.671

Review 4.  Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.

Authors:  Patricia A Shi; Larry L Luchsinger; John M Greally; Colleen S Delaney
Journal:  Curr Opin Hematol       Date:  2022-08-29       Impact factor: 3.218

Review 5.  Enhancing Matured Stem-Cardiac Cell Generation and Transplantation: A Novel Strategy for Heart Failure Therapy.

Authors:  Ampadu O Jackson; Ganiyu A Rahman; Kai Yin; Shiyin Long
Journal:  J Cardiovasc Transl Res       Date:  2020-11-30       Impact factor: 4.132

Review 6.  Immunologic Rejection of Transplanted Retinal Pigmented Epithelium: Mechanisms and Strategies for Prevention.

Authors:  Carson C Petrash; Alan G Palestine; M Valeria Canto-Soler
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

7.  Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives.

Authors:  Hye-Yeong Jo; Hyo-Won Han; Inuk Jung; Ji Hyeon Ju; Soon-Jung Park; Sunghwan Moon; Dongho Geum; Hyemin Kim; Han-Jin Park; Sun Kim; Glyn N Stacey; Soo Kyung Koo; Mi-Hyun Park; Jung-Hyun Kim
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

Review 8.  Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics.

Authors:  David T Paik; Mark Chandy; Joseph C Wu
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 9.  Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges.

Authors:  Elizabeth Ford; Jodie Pearlman; Travis Ruan; John Manion; Matthew Waller; Gregory G Neely; Leslie Caron
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

10.  Umbilical Cord Blood Units Cryopreserved in the Public Cord Blood Bank: A Breakthrough in iPSC Haplobanking?

Authors:  Eun Youn Roh; Sohee Oh; Jong Hyun Yoon; Byoung Jae Kim; Eun Young Song; Sue Shin
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.